Join the Oncology Voice Network. Join for Free
Field Medical Execution Despite Limited Resources
Neurology MSLs managing MSL teams virtual platforms impact engaging KOLs strategies future of MSL role

Field Medical Execution Despite Limited Resources


Share This Article


Summary

In this episode, Ed Cunningham delves into his extensive background in Neurology MSLs and shares insights on managing MSL teams, including the role of outsourcing. He explores the impact of virtual platforms and technology on MSL interactions, and offers strategies for engaging KOLs in the post-COVID landscape. Ed addresses the challenges of maintaining effectiveness in large territories, and discusses metrics for performance measurement in Medical Affairs. The conversation extends to the future of the MSL role, hybrid work models, and the evolving value of MSLs to stakeholders. The episode concludes with closing remarks and sponsorship from Synovian Pharmaceuticals.

My guest today is Ed Cunningham, Executive Director, Neurology MSLs with Sunovian Pharmaceuticals shares insights for Field Medical Execution Despite Limited Resources

Ed discusses…

πŸ‘‰ How to lead MSL teams with limited resources
πŸ‘‰ The importance of outsourcing to support field-based efforts and activities
πŸ‘‰ Virtual and alternative platforms to share data and gather insights
πŸ‘‰ What are best practices for prioritizing KOL engagement and tracking
πŸ‘‰ How budget plays a factor
πŸ‘‰ How an MSL can maintain effectiveness in a very large territory
πŸ‘‰ How an MSL can adapt a territory plan to accomplish objectives

Click for Source
Neurology MSLs, managing MSL teams, virtual platforms impact, engaging KOLs strategies, future of MSL role

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Press Release
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
OVN Avatar OVN Staff

Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
OVN Avatar A. Haslam, M.S. Kim, V. Prasad

Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020

Podcast
The Ideal Roadmap for New MSLs
Partner Avatar MSL Talk: Tom Caravela, Sarah Snyder

The Ideal Roadmap for New MSLs

Explore OVN